ChinaDaily Briefs

Daily Brief China: PDD Holdings Inc, Tencent, MTR Corp, China Communications Construction, Keep Inc, Alibaba (ADR), China Shineway Pharmaceutical, Huawei Technology, Times China, Sino-Ocean Group and more

In today’s briefing:

  • Pinduoduo (PDD) Short Review: Third-Party Retailers “Bombarded” Direct Sales
  • China Internet Weekly (10Apr2023): Tencent, Douyin, Bilibili, Alibaba, Baidu, World Perfect
  • MTR (66 Hk): Now if You Missed the First Bounce
  • China Comm Const (1800 HK): We See More Stories Coming
  • The Meteoric Rise of China’s Hottest Fitness App Keep and Its Ambitious Plans to Go Public
  • [Alibaba (BABA US, BUY, TP US$109) Earnings Preview]: Recovery Is on the Way Amid Weakness in C1Q23
  • China Shineway Pharmaceutical (2877.HK) – Strong Growth Momentum Is Expected to Continue in 2023
  • Huawei’s 2022 Profit Plunges 69% Amid Sanctions and Heavy R&D Outlays
  • Morning Views Asia: China Vanke, Lenovo, Sunny Optical, Times China, Yanlord Land
  • Sino-Ocean – ESG Report – Lucror Analytics

Pinduoduo (PDD) Short Review: Third-Party Retailers “Bombarded” Direct Sales

By Ming Lu

  • PDD’s small retailers bought out products of direct sales and claimed full refund.
  • The story happened to Alibaba more than ten years ago.
  • It can be hard for PDD to enter the high quality market.

China Internet Weekly (10Apr2023): Tencent, Douyin, Bilibili, Alibaba, Baidu, World Perfect

By Ming Lu

  • Tencent authorized video editing right to Douyin, one of its main competitors.
  • Some of Bilibili’s video uploaders cannot survive the hard time.
  • Both Alibaba and Baidu launched their ChatGPT-like apps, but Baidu’s app was .

MTR (66 Hk): Now if You Missed the First Bounce

By Henry Soediarko

  • MTR Corp (66 HK) is the lagging stock in Hong Kong although it is a key beneficiary to more Chinese tourists that will arrive soon.
  • HK Government has launched a few initiatives to invite tourists to visit Hong Kong that will boost higher ridership for the company. 
  • It is now trading at the level prior to COVID with the potential of higher earnings that will come from the ridership increase. 

China Comm Const (1800 HK): We See More Stories Coming

By Osbert Tang, CFA

  • China Communications Construction (1800 HK) is expected to generate higher shareholder return through improvement in profitability/cash flow, spin-off, asset disposal and issuance of REITs.
  • Operationally, backlog reached Rmb3.39trn at end-FY22, enough to cover 3.9x FY23F revenue. It expects revenue to grow at least 7% and new contract by no less than 9.8% in FY23. 
  • Employee incentive scheme has been adopted with targets including FY21-23 earnings CAGR of at least 8% and FY23 return on net assets of 7.7%. This aligns employee interests with shareholders’. 

The Meteoric Rise of China’s Hottest Fitness App Keep and Its Ambitious Plans to Go Public

By Andrei Zakharov

  • Keep Inc., the sports technology unicorn and the largest fitness app in China, has renewed its application proof in Hong Kong. Goldman Sachs and CICC are leading the upcoming IPO.
  • With a mission to make the world move, the fitness app has been making waves in the fitness industry with its innovative approach to online fitness.
  • Keep fitness app has been downloaded over 300M times since inception and there were 370M+ fitness users in China in 2022, the world’s largest market globally.

[Alibaba (BABA US, BUY, TP US$109) Earnings Preview]: Recovery Is on the Way Amid Weakness in C1Q23

By Shawn Yang

  • We expect BABA to report C1Q23 (F4Q23) top-line and non-IFRS net income (5.0%) and (5.9%) vs. consensus, respectively, 
  • Due to: 1) weak sales of Taobao, Tmall and 1P sales; 2) the on-going move of a key Cloud client; 
  • We maintain US$109 TP as: 1) Taobao and Tmall sales shows recovery trend; 2) near-term benefit of unveiling its LLM AI; and 3) benefit from the new business unit structure.

China Shineway Pharmaceutical (2877.HK) – Strong Growth Momentum Is Expected to Continue in 2023

By Xinyao (Criss) Wang

  • Shineway’s 2022 performance was outstanding.Its TCM formula granules business would seize more market share and maintain strong growth momentum, which would continue to be the main performance driver in 2023.
  • Considering obvious policy preferences and lower price reduction of TCM in VBP, we recommend investors to leave a place for TCM company in portfolio, and Shineway deserves investors’ attention.
  • Shineway is cash rich. Together with promising growth potential and solid financial performance, Shineway’s share price is expected to perform well, which could be a good trading target for investors.

Huawei’s 2022 Profit Plunges 69% Amid Sanctions and Heavy R&D Outlays

By Caixin Global

  • Huawei Technologies Co. posted its lowest profit margin ever for 2022 but managed a slight revenue gain in the third year of U.S. sanctions that forced the Chinese electronics giant to diversify its business into new sectors from cloud computing to automobiles.
  • The company reported net profit of 35.6 billion yuan ($5.18 billion) for 2022, a 69% decline from 2021, on revenue of 642.3 billion, up 0.9% from a year ago.
  • Its profit margin fell to a record low of 5.5%.

Morning Views Asia: China Vanke, Lenovo, Sunny Optical, Times China, Yanlord Land

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Sino-Ocean – ESG Report – Lucror Analytics

By Charles Macgregor

Lucror Analytics’ ESG Scores are based on a 3-tiered scale and are adjusted for Controversies (if applicable).
We assess Sino-Ocean’s ESG as “Weak”, in line with its “Weak” Governance score. That said, the company has an “Adequate” Environmental score and a “Strong” score for the Social pillar. Controversies are “Material”, but Disclosure is “Strong”.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars